Anetta Bolejko
Associate professor, Principal investigator
A pilot study of an organised population‐based testing programme for prostate cancer
Author
Summary, in English
Objective
To determine the feasibility of a digitally automated population-based programme for organised prostate cancer testing (OPT) in Southern Sweden.
Patients and Methods
A pilot project for a regional OPT was conducted between September 2020 and February 2021, inviting 999 randomly selected men aged 50, 56, or 62 years (y). Risk stratification was based on PSA, PSA density (PSAD), and biparametric prostate MRI. Men with a PSA level of 3–99 ng/mL had an MRI, and men with elevated PSA (≥ 3 ng/mL) had a urological check-up, including a DRE and TRUS. Indications for targeted and/or systematic transrectal prostate biopsies were suspicious lesions on MRI (prostate imaging reporting and data system [PI-RADS] 4–5) and/or PSAD > 0.15 ng/mL/cm3. Additional indications for prostate biopsies were palpable tumours, PSA ratio
Results
A total of 418 men had a PSA test (42%), with increasing participation rates by age (50y, 38%; 56y, 44%; and 62y, 45%). Among these, 35 men (8%) had elevated PSA (≥ 3 ng/mL: 50y, 1/139; 56y, 10/143; and 62y, 24/146). On MRI, 16 men (48%) had a negative scan (PI-RADS 0.15 ng/mL/cm3 or a suspicious finding on TRUS. Prostate cancer was diagnosed in ten men. Six men underwent active treatment, whereas four men were assigned to active surveillance.
Conclusion
Our OPT model is feasible from an operational point of view, but due to the limited scale of this study no conclusions can be made regarding the efficacy of the diagnostic model or outcome
To determine the feasibility of a digitally automated population-based programme for organised prostate cancer testing (OPT) in Southern Sweden.
Patients and Methods
A pilot project for a regional OPT was conducted between September 2020 and February 2021, inviting 999 randomly selected men aged 50, 56, or 62 years (y). Risk stratification was based on PSA, PSA density (PSAD), and biparametric prostate MRI. Men with a PSA level of 3–99 ng/mL had an MRI, and men with elevated PSA (≥ 3 ng/mL) had a urological check-up, including a DRE and TRUS. Indications for targeted and/or systematic transrectal prostate biopsies were suspicious lesions on MRI (prostate imaging reporting and data system [PI-RADS] 4–5) and/or PSAD > 0.15 ng/mL/cm3. Additional indications for prostate biopsies were palpable tumours, PSA ratio
Results
A total of 418 men had a PSA test (42%), with increasing participation rates by age (50y, 38%; 56y, 44%; and 62y, 45%). Among these, 35 men (8%) had elevated PSA (≥ 3 ng/mL: 50y, 1/139; 56y, 10/143; and 62y, 24/146). On MRI, 16 men (48%) had a negative scan (PI-RADS 0.15 ng/mL/cm3 or a suspicious finding on TRUS. Prostate cancer was diagnosed in ten men. Six men underwent active treatment, whereas four men were assigned to active surveillance.
Conclusion
Our OPT model is feasible from an operational point of view, but due to the limited scale of this study no conclusions can be made regarding the efficacy of the diagnostic model or outcome
Department/s
- Urological cancer, Malmö
- Radiology Diagnostics, Malmö
- Diagnostic Radiology, (Lund)
- LU Profile Area: Light and Materials
- LTH Profile Area: Photon Science and Technology
- EpiHealth: Epidemiology for Health
- eSSENCE: The e-Science Collaboration
Publishing year
2024
Language
English
Pages
87-95
Publication/Series
BJU International
Volume
133
Issue
1
Document type
Journal article
Publisher
Wiley-Blackwell
Topic
- Urology and Nephrology
- Cancer and Oncology
Status
Published
Research group
- Urological cancer, Malmö
- Radiology Diagnostics, Malmö
ISBN/ISSN/Other
- ISSN: 1464-4096